Adicet Bio (ACET) Expected to Announce Quarterly Earnings on Tuesday

Adicet Bio (NASDAQ:ACET) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Adicet Bio to post earnings of ($0.36) per share for the quarter.

Adicet Bio (NASDAQ:ACET) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Price Performance

Shares of ACET stock opened at $0.78 on Monday. The firm has a 50-day moving average of $0.91 and a 200-day moving average of $1.12. The company has a market cap of $64.71 million, a P/E ratio of -0.46 and a beta of 1.97. Adicet Bio has a one year low of $0.74 and a one year high of $2.43.

Analysts Set New Price Targets

ACET has been the subject of several analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Adicet Bio in a report on Friday, March 7th. JMP Securities reiterated a “market perform” rating on shares of Adicet Bio in a research report on Thursday, February 6th. Finally, StockNews.com lowered shares of Adicet Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.50.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.